Juno Therapeutics, Inc. (JUNO) Receives Average Rating of “Buy” from Analysts
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) have received an average recommendation of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $30.97.
A number of brokerages have weighed in on JUNO. Vetr upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $28.85 target price for the company in a report on Monday. Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a report on Tuesday, July 11th. BidaskClub upgraded Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 27th. Wedbush restated a “neutral” rating and set a $24.00 price objective on shares of Juno Therapeutics in a report on Tuesday, June 6th. Finally, BTIG Research downgraded Juno Therapeutics from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $12.00 to $23.00 in a report on Tuesday, June 6th.
In other Juno Therapeutics news, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total value of $262,500.00. Following the transaction, the chief financial officer now owns 736,189 shares of the company’s stock, valued at $22,085,670. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Anthony B. Evnin acquired 9,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was acquired at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the transaction, the director now owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The disclosure for this purchase can be found here. In the last three months, insiders sold 41,500 shares of company stock worth $1,230,360. Insiders own 15.26% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of JUNO. Great West Life Assurance Co. Can boosted its position in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares in the last quarter. Nisa Investment Advisors LLC acquired a new position in Juno Therapeutics during the first quarter valued at $200,000. Russell Investments Group Ltd. acquired a new position in Juno Therapeutics during the fourth quarter valued at $204,000. Tudor Investment Corp Et Al acquired a new position in Juno Therapeutics during the fourth quarter valued at $215,000. Finally, Opus Point Partners Management LLC boosted its position in Juno Therapeutics by 65.9% in the fourth quarter. Opus Point Partners Management LLC now owns 11,478 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 4,560 shares in the last quarter. 64.51% of the stock is currently owned by institutional investors and hedge funds.
Juno Therapeutics (NASDAQ JUNO) opened at 27.26 on Monday. The company has a 50 day moving average price of $24.94 and a 200 day moving average price of $22.57. The firm’s market capitalization is $2.84 billion. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $35.04.
Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by $0.01. The business had revenue of $19.30 million during the quarter, compared to the consensus estimate of $16 million. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The company’s revenue for the quarter was up 96.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.78) earnings per share. Analysts anticipate that Juno Therapeutics will post ($2.99) earnings per share for the current fiscal year.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.